Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS

Frontiers in Neurology - Switzerland
doi 10.3389/fneur.2019.00229
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Frontiers Media SA

Related search

Challenges Assessing Clinical Endpoints in Early Huntington Disease

Movement Disorders
Neurology
2010English

Design and Inference in Phase II/III Clinical Trials Incorporating Monitoring of Multiple Endpoints.

English

Exploring Novel Endpoints for Clinical Trials in Kidney Disease: Challenges and Opportunities

Kidney International Reports
Nephrology
2017English

Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD

Journal of Hepatology
Hepatology
2019English

Prodromal Markers in Parkinson’s Disease: Limitations in Longitudinal Studies and Lessons Learned

Frontiers in Aging Neuroscience
AgingCognitive Neuroscience
2016English

Moving Forward in Clinical Trials for ALS: Motor Neurons Lead the Way Please

Drug Discovery Today
Drug DiscoveryPharmacology
2014English

Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials

Frontiers in Immunology
AllergyImmunology
2017English

Role of Inflammatory Markers in Takayasu Arteritis Disease Monitoring

BMC Neurology
MedicineNeurology
2014English

Pharmacodynamic Endpoints as Clinical Trial Objectives to Answer Important Questions in Oncology Drug Development

Seminars in Oncology
OncologyHematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy